Nurses' perceptions on the usability of the Hyrimoz® Sensoready® autoinjector device.

Background: Hyrimoz^® (Sandoz adalimumab biosimilar) became available in the USA in July 2023, and is administered subcutaneously using a pre-filled autoinjector device, the Hyrimoz Sensoready^® pen. As nurses are often responsible for training patients in the use of autoinjectors, this survey aimed to assess gastroenterology nurses' perceptions of autoinjectors in the USA.

Methods: Eligible participants included nurses in the USA currently working within a gastroenterology practice with experience managing inflammatory bowel disease and with reference to adalimumab, Humira^®. Participants were sent the Hyrimoz Sensoready pen, which was opened during a web-assisted telephone interview. The survey assessed the importance of specified autoinjector device attributes as well as perceptions regarding both the Humira and Hyrimoz Sensoready autoinjector devices.

Results: A total of 123 nurses completed the survey. Participants rated simplicity of use, ease of performing self-injection, ease of learning to use the pen, ability to use an autoinjector pen independently and ease of preparation as the most important autoinjector attributes. When evaluating devices individually, participants awarded higher ratings to the Hyrimoz Sensoready pen over the Humira pen for all evaluated attributes. The greatest differences were reported for visual feedback mechanisms, ease of performing self-injection and the process to initiate injection. When directly comparing the devices, participants preferred the Hyrimoz Sensoready pen over the Humira pen overall, and for all individual attributes. Visual feedback and buttonless activation were the main qualitative features driving this overall preference.

Conclusion: Gastroenterology nurses in the USA expressed strong preferences for the Hyrimoz Sensoready pen versus the Humira pen when rating each device individually, and in direct quantitative and qualitative comparisons.